French drugmaker Sanofi (Euronext: SAN) looked set to close Friday’s trading 2% down after presenting its latest financial results and outlook for 2023.
The results for both the fourth quarter and entirety of 2022 showed healthy levels of growth, but Sanofi’s forecast for the year ahead left investors unimpressed.
"Dupixent (dupilumab) and vaccines continue to be our leading growth drivers"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze